logo

AARTIDRUGS vs SANOFI: Stock Comparison

AARTI DRUGS vs SANOFI INDIAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

SANOFI INDIA is the larger company by market capitalisation. AARTI DRUGS shows faster revenue growth, while SANOFI INDIA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 2; SANOFI leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSSANOFI

Valuation lens

What price are you paying?

Market CapContext only
₹3,478 Cr
₹6,529 Cr
P/E RatioSANOFI has the lower reading
18.19x
0x ✓
P/B RatioSANOFI has the lower reading
2.25x
0x ✓
EPSSANOFI has the higher reading
₹20.93
₹39.64 ✓
Book ValueContext only
₹169.79
₹325.31
Dividend YieldSANOFI has the higher reading
0.5%
4.36% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SANOFI is the larger company
₹6,529 Cr vs ₹3,478 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 18.19x
P/B Ratio
SANOFI has a lower P/B
0x vs 2.25x
EPS
SANOFI has higher earnings per share
₹39.64 vs ₹20.93
Dividend Yield
SANOFI has a higher dividend yield
4.36% vs 0.5%
Revenue Growth (TTM YoY)
AARTIDRUGS has faster revenue growth
6.4% vs -11.9%
EPS Growth (TTM YoY)
AARTIDRUGS has faster EPS growth
-12% vs -14.1%
ROE
SANOFI has a higher ROE
41.35% vs 12.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSSANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSSANOFI
Live Price₹380.05₹2,831.1
Day Change-2.2%0.13%
Volume1.59 L15,277
52-Week High₹534₹4,898
52-Week Low₹318.95₹2,820.1
Distance from 52W High-28.83%-42.2%

Valuation

MetricAARTIDRUGSSANOFI
Market Cap₹3,478 Cr₹6,529 Cr
P/E Ratio18.19x0x
P/B Ratio2.25x0x
EPS₹20.93₹39.64
Book Value₹169.79₹325.31
Dividend Yield0.5%4.36%

Growth

MetricAARTIDRUGSSANOFI
Revenue Growth (TTM YoY)6.4%-11.9%
EPS Growth (TTM YoY)-12%-14.1%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricAARTIDRUGSSANOFI
ROE12.05%41.35%
ROCE10.64%64.11%
Net Margin7.6%19.26%
Operating Margin9.19%23.62%
Debt to Equity0.3x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricAARTIDRUGSSANOFI
Promoter Holding54.07%▼ 0.36 pp0%
FII Holding2.26%▲ 0.74 pp5.69%▲ 0.05 pp
DII Holding10.24%▼ 0.05 pp19.87%▼ 1.26 pp
Public Holding33.43%▼ 0.32 pp14.04%▲ 1.21 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and SANOFI INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.